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Abstract
Background Chronic heart failure (CHF) leads to diaphragm myopathy that signiﬁcantly impairs quality of life and worsens
prognosis. In this study, we aimed to assess the efﬁcacy of a recently discovered small-molecule inhibitor of MuRF1 in treating
CHF-induced diaphragm myopathy and loss of contractile function.
Methods Myocardial infarction was induced in mice by ligation of the left anterior descending coronary artery. Sham-
operated animals (sham) served as controls. One week post-left anterior descending coronary artery ligation animals were
randomized into two groups—one group was fed control rodent chow, whereas the other group was fed a diet containing
0.1% of the compound ID#704946—a recently described MuRF1-interfering small molecule. Echocardiography conﬁrmed
development of CHF after 10 weeks. Functional and molecular analysis of the diaphragm was subsequently performed.
Results Chronic heart failure induced diaphragm ﬁbre atrophy and contractile dysfunction by ~20%, as well as decreased
activity of enzymes involved in mitochondrial energy production (P< 0.05). Treatment with compound ID#704946 in CHF mice
had beneﬁcial effects on the diaphragm: contractile function was protected, while mitochondrial enzyme activity and up-reg-
ulation of the MuRF1 and MuRF2 was attenuated after infarct.
Conclusions Our murine CHF model presented with diaphragm ﬁbre atrophy, impaired contractile function, and reduced
mitochondrial enzyme activities. Compound ID#704946 rescued from this partially, possibly by targeting MuRF1/MuRF2.
However, at this stage of our study, we refrain to claim speciﬁc mechanism(s) and targets of compound ID#704946, because
the nature of changes after 12weeks of feeding is likely to be complex and is not necessarily caused by direct mechanistic effects.
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Introduction
Skeletal muscle wasting and weakness develops in several
clinical conditions including chronic heart failure (CHF),
pulmonary hypertension, cancer, immobilization, and sepsis.
In CHF, this loss of muscle mass and function occurs in both
limb and respiratory muscle and is associated with exercise
intolerance, dyspnoea, and prognosis.1–4 Therefore, reducing
muscle wasting as a therapeutic intervention has the
potential to modulate quality of life and reduce mortality.
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Mechanistically, the activation of so-called atrogins leading
to enhanced muscle protein degradation, via the ubiquitin
proteasome system (UPS) or autophagosome, is a central
step5–7 in muscle wasting. In this process, the activation of
the muscle ring ﬁnger protein 1 (MuRF1) is believed to drive
the poly-ubiquitylation of proteins scheduled for degradation
via the UPS.8,9 The central role of MuRF1 in modulating
muscle mass is further supported by observations of up-
regulated MuRF1 expression in numerous clinical conditions
associated with muscle wasting,5,10 as well as after pharmaco-
logical intervention (e.g. induction of muscle atrophy by
glucocorticoids, inﬂammatory cytokines, or reactive oxygen
species),11–13 while its inactivation can partially abolish
ﬁbre atrophy.11,12,14 Accordingly, signiﬁcant effort has been
invested to down-regulate MuRF1 therapeutically, for exam-
ple, by a small-molecule inhibition,15 adenoviral-mediated
knock-down,16,17 or by exercise training,18 where down-
regulation in expression correlated with reduced muscle
wasting.
We recently described a small molecule (compound
ID#704946, molecular weight 490 Da) that inhibited MuRF1
expression/activity in vivo and was able to attenuate skeletal
muscle atrophy and dysfunction in mice treated with
monocrotaline to induce right ventricular hypertrophy and
subsequent cardiac cachexia.19 In that earlier study, the
compound ID#704946 was given 1 week before monocrota-
line treatment was initiated, complicating the interpretation
of therapeutic applicability. In the present study, we there-
fore addressed the question of compound ID#704946’s
efﬁcacy in a more clinically relevant cardiac disease model
[myocardial infarction (MI)-induced heart failure] and a set-
ting of secondary prevention (ﬁrst treatment dose post-MI).
Because of the key role MuRF1 plays in muscle atrophy
following cardiac failure, we hypothesized that compound
feeding may inﬂuence muscle wasting and loss of function
in this clinically relevant animal model. Our results indicate
muscle atrophy and dysfunction as partially reversed in
compound-treated animals and the phenotypic rescue to be
mechanistically associated with a protection of mitochondrial
function as documented by metabolic energetics and
proteomic homeostasis.
Materials and methods
Animals and study design
C57/BL6 female mice (n = 70) underwent an MI to induce CHF
or sham surgery, where a surgical silk suture ligated the left
anterior descending coronary artery (LAD) as previously de-
scribed.20,21 One week after LAD ligation, echocardiography
was performed to conﬁrm MI, and only mice with a large
infarct [left ventricular ejection fraction (LVEF) <20%] were
subsequently randomized into either receiving normal chow
(CHF, n = 11) or chow supplemented with compound (0.1%
of compound ID#704946, CHF + 704946, n = 12) as recently
described.19 Sham animals that underwent surgery but where
the LAD was not ligated served as controls and were fed
normal chow (sham, n = 15). Nine weeks after randomization,
echocardiography was repeated, and animals were sacriﬁced
to collect tissues for functional and molecular characteriza-
tion (Figure 1A). All experiments and procedures were
approved by the local Animal Research Council, University
of Leipzig, and the Landesbehörde Sachsen (TVV 36/15).
Echocardiography and histology of the heart
As previously described,20 echocardiography was performed
in M-mode at 1 and 10 weeks post-surgery, with left
ventricular end-diastolic (LVEDD) and systolic (LVESD) diame-
ters assessed to allow calculation of left ventricular (LV) frac-
tional shortening (LVFS = [LVEDD  LVESDLVEDD] × 100).
At sacriﬁce, the medial portion of the heart was ﬁxed in
4% phosphate-buffered saline (PBS)–buffered formalin, and
sections (2 μm) stained with Picosirius red were then
mounted on glass slides for subsequent analysis. A computer
imaging software (Analysis 3.0, Olympus Soft Imaging
Solutions GmbH, Münster, Germany) was then used to
demarcate the infarct boundary, deﬁned by a signiﬁcant loss
in LV myocardium tissue and presence of ﬁbrotic tissue (i.e.
a thinning in the LV wall ±2 SDs of mean wall thickness), as
previously described.20 Average infarct size (%) was then
quantiﬁed as the ratio of infarct circumference-to-overall
LV circumference.
Contractile function
A ﬁbre bundle from the diaphragm was isolated to allow
in vitro contractile function to be assessed using a length-
controlled lever system (301B, Aurora Scientiﬁc Inc., Aurora,
Canada), as previously described.19,22 Brieﬂy, a muscle bundle
was mounted vertically in a buffer-ﬁlled organ bath (~22 °C),
set at optimal length, and after 15 min was stimulated via a
force–frequency protocol using 1–300 Hz (600 mA, 500 ms
train duration, and 0.25 ms pulse width). The muscle was
then subjected to a force–velocity protocol where it was
allowed to shorten against external loads (80–10% of the
maximal tetanic force; each separated by 1 min) after being
stimulated at 150 Hz for 300 ms. Shortening velocity was
determined 10 ms after the ﬁrst change in length and on
the linear section of the transient (DMA software, Aurora
Scientiﬁc Inc.). Force (N) was normalized to muscle cross-
sectional area (CSA; cm2) by dividing muscle mass (g) by the
product of Lo (cm) and estimated muscle density (1.06),
which allowed speciﬁc force in N/cm2 to be calculated.
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Figure 1 An overview of the study design (A). Animals at an age of 12 weeks were either subjected to myocardial infarction to induce chronic heart
failure (CHF) or sham operated. One week after myocardial infarction echocardiography was performed to conﬁrm reduced contractility. Animals with
a left ventricular ejection fraction (LVEF) <20% were randomized into groups either receiving normal mouse chow (CHF) or chow supplemented with
compound ID#704946 (CHF + 704946). Nine weeks after randomization echocardiography was repeated, animals were sacriﬁced, and tissue was col-
lected for subsequent analysis. Echocardiographic analyses 1 week after sham operation or myocardial infarction and prior randomization revealed a
signiﬁcant reduction in LVEF (B) and fractional shortening (FS) (C) in CHF and CHF + 704946mice. Representative images of myocardial sections stained
with Picosirius red after the treatment period are shown (D) documenting clear ﬁbrosis in the CHF and CHF + 704946 animals. LAD, left anterior de-
scending coronary artery.
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Shortening velocity was normalized to optimal muscle length
(in Lo/s), while power was calculated for each load as the
product of shortening velocity and speciﬁc force (in W/cm2).
Diaphragm analyses
Parafﬁn-embedded diaphragm sections (3 μm) were stained
with periodic acid–Schiff, and ﬁbre CSA was subsequently
evaluated by imaging software (ImageJ, open source soft-
ware). For quantiﬁcation of ﬁbre-type distribution, parafﬁn
sections (3 μm) were incubated for 1 h after antigen retrieval
with a primary antibody to slow myosin heavy chain (1/75 di-
lution, Abcam, Cambridge, UK). After extensive washing with
PBS, the sections were incubated with an anti-mouse peroxi-
dase secondary antibody (1 h, Sigma, Taufkirchen, Germany,
1:250), followed by AEC (3-amino-9-ethylcarbazole) staining.
Positive-stained (type I ﬁbres) and negative-stained ﬁbres
(type II ﬁbres) were counted by image analysis software
(ImageJ), and per cent distribution was calculated.
Proteomic and western blot analysis
Mass spectrometry-based proteomic analysis was performed
at the DZHK Core Facility, Bad Nauheim, Germany (see details
in the Supporting Information). Obtained MS raw data were
processed by MaxQuant (1.6.0.1)23 using the Andromeda
search engine and the Uniprot database for Mus musculus
(as of 20 April 2017). At a false discovery rate of 1%24 (both
peptide and protein levels; see also Supporting Information,
Figure S1), >2600 protein groups were identiﬁed. The reduc-
tive dimethylation protocol employed25 yielded pairwise
relative comparative quantitation (ratios) between proteins
from CHF + 704946, CHF, and sham conditions, which were
statistically queried for signiﬁcant differences (see details in
the Supporting Information). Selected polypeptides detected
as signiﬁcantly changing were validated using western
blotting.
For western blot analyses, frozen diaphragm was homoge-
nized in relaxing buffer (90 mmol/L HEPES, 126 mmol/L
potassium chloride, 36 mmol/L sodium chloride, 1 mmol/L
magnesium chloride, 50 mmol/L EGTA, 8 mmol/L ATP, and
10 mmol/L creatine phosphate, pH 7.4) containing a protease
inhibitor mix (Inhibitor Mix M, Serva, Heidelberg, Germany)
and sonicated. Protein concentration of the supernatant
was determined (bicinchoninic acid assay, Pierce, Bonn,
Germany), and aliquots (5–20 μg) were separated by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis. Proteins
were transferred to a polyvinylidene ﬂuoride membrane and
incubated overnight at 4 °C using the following primary
antibodies: porin and telethonin (both 1/1000, Abcam,
Cambridge, UK), MRPS-5 (1/500, Thermo Fisher, Rockford, IL,
USA), MuRF1 and MuRF2 (both 1/1000; raised in the Labeit
laboratory26 and also commercially available from Myomedix,
Neckargemünd, Germany), and Tom20 (1:200, Santa Cruz
Biotechnologies, Heidelberg, Germany). Membranes were
subsequently incubated with a horseradish peroxidase-
conjugated secondary antibody, speciﬁc bands were visualized
by enzymatic chemiluminescence (Super Signal West Pico,
Thermo Fisher Scientiﬁc Inc., Bonn, Germany), and densitom-
etry was quantiﬁed using a one-dimensional scan software
package (Scanalytics Inc., Rockville, MD, USA). Measurements
were normalized to the loading control GAPDH (1/30 000;
HyTest Ltd, Turku, Finland) or α-tubulin (1:1000, Santa Cruz
Biotechnologies). All data are presented as fold change
relative to sham.
Enzyme activity measurements
Diaphragmatic tissue was homogenized in relaxing buffer,
and aliquots were used for enzyme activity measurements.
Enzyme activities for lactate dehydrogenase (EC 1.1.1.27),
pyruvate kinase (EC 2.7.1.40), succinate dehydrogenase
(SDH, EC 1.3.5.1), citrate synthase (CS, EC 2.3.3.1), β-
hydroxyacyl-COA dehydrogenase (EC 1.1.1.35), and mito-
chondrial complex I were measured spectrophotometrically
as previously described in detail.27–31 Enzyme activity data
are presented as the fold change relative to sham.
Differential scanning ﬂuorimetry analysis
‘MuRF1 central’ fragment was expressed as previously de-
scribed32 and used in differential scanning ﬂuorimetry (DSF)
experiments at 75 μmol/L ﬁnal concentration. Compound
ID#704946 was diluted from a 10 mmol/L stock in DMSO to
100 μmol/L in PBS as DSF assay buffer, resulting in a ﬁnal con-
centration of 1% DMSO. After 1 h pre-incubation at room
temperature, the aqueous protein solutions were soaked into
capillaries and placed into a Prometheus NT.48 nanoDSF de-
vice (NanoTemper Technologies, Munich, Germany). Changes
in the intrinsic tryptophan or tyrosine ﬂuorescence that oc-
curred after light-emitting diode laser excitement upon pro-
tein unfolding in a thermal gradient were detected at 330
and 350 nm, respectively.
Cell culture, reverse transcription PCR, and
transcriptome analysis
C2C12 myotubes19 were incubated with or without com-
pound ID#704946 for 20 min at a ﬁnal concentration of
10 μmol/L. After the incubation period, total RNA was iso-
lated (miRNeasy Mini Kit, Qiagen, Hilden, Germany) and re-
verse transcribed into cDNA (Revert AIDTM H Minus First
Strand Synthesis Kit, Thermo Fisher Scientiﬁc Inc.) using
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oligo-dT primers. Real-time PCR was performed using the
CFX96TM or CFX384TM Real-Time PCR System (Bio-Rad, Her-
cules, CA, USA) and Maxima SYBR Green qPCR Kit (Thermo
Fisher Scientiﬁc Inc.). Primers used for real-time–reverse
transcription PCR analysis are listed in Supporting Informa-
tion, Table S1. Relative quantiﬁcation of gene expression
was calculated by CT method with Polr2a and Tbp as house-
keeping genes as recently described.33
Transcriptome analysis was performed as brieﬂy outlined.
Barcoded stranded mRNA sequence libraries were prepared
from high-quality total RNA samples (~200 ng per sample)
using the Illumina TruSeq RNA Sample Preparation v2 Kit
(Illumina, San Diego, CA, USA) implemented on the liquid
handling robot Beckman FXP2. Obtained libraries were
pooled in equimolar amounts; 1.8 pmol/L solution of this
pool was loaded on the Illumina sequencer NextSeq 500
and sequenced unidirectionally, generating ~500 million
reads, each 85 bases long. Base calling of the sequencing
run was performed using bcl2fastq v2.20 (Illumina, San Diego,
CA, USA).
Table 1 Animal characteristics after 10 weeks of intervention
Sham (n = 15) CHF (n = 11) CHF + 704946 (n = 12)
Physical
Body weight (g) 22.6 ± 0.5 22.4 ± 0.6 23.8 ± 0.4
Heart-to-body weight (g/mg) 5.03 ± 0.11 7.87 ± 0.55*** 7.52 ± 0.57***
Lung weight (wet/dry) 4.16 ± 0.07 4.48 ± 0.06* 4.47 ± 0.10*
Histology
LV infarct size (%) — 30.5 ± 4.6 27.1 ± 2.9
Echocardiography
LVEDD (mm) 3.8 ± 0.1 6.2 ± 0.2*** 5.9 ± 0.2***
LVESD (mm) 2.6 ± 0.1 5.8 ± 0.3*** 5.3 ± 0.2***
LVEF (%) 59.6 ± 2.7 16.1 ± 2.9*** 21.1 ± 2.5***
LVFS (%) 31.8 ± 1.9 7.5 ± 1.4*** 9.9 ± 1.2***
CHF, chronic heart failure; LV, left ventricle; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD,
left ventricular end-systolic diameter; LVFS, left ventricular fractional shortening.
Data are presented as mean ± standard error of the mean.
*P < 0.05 vs. sham.
***P < 0.001 vs. sham.
Figure 2 In vitro contractile function of diaphragm ﬁbre bundles, as assessed during isometric (A, B) and isotonic contractions (C, D). Comparing max-
imal speciﬁc force (B) and maximal power (D), chronic heart failure (CHF) animals demonstrated a 21 and 28% reduction, respectively, which was sig-
niﬁcantly attenuated by ID#704948. Data are presented as mean ± standard error of the mean.
*
P < 0.05,
**
P < 0.01,
***
P < 0.001 vs. CHF,
§
P < 0.05,
and §§P < 0.01 vs. CHF + 704946.
MuRF inhibition in chronic heart failure 5
Journal of Cachexia, Sarcopenia and Muscle 2019
DOI: 10.1002/jcsm.12448
Sequencing reads were aligned onto Mus musculus ge-
nome reference (GRCm38.p6-mm10) with STAR aligner.34
Read counting was performed using the STAR’s in-built
implementation of HTSeq-count.35 Transcriptomic analysis
was carried out using the DESeq2 v1.22.2 package.36
Statistical analyses
Data are presented as mean ± standard error of the mean.
One-way analysis of variance followed by Bonferroni post
hoc was used to compare groups, while two-way repeated
measures analysis of variance followed by Bonferroni post
hoc was used to assess contractile function (GraphPad Prism).
Signiﬁcance was accepted as P < 0.05.
Results
Mouse model of chronic heart failure
One week post-MI, 23 out of 70 LAD-ligated mice (32%) ex-
hibited a signiﬁcant impairment of cardiac function, as evi-
denced by an ~75% reduction in LVEF (Figure 1B) and ~72%
reduction in LVFS (Figure 1C) as compared with sham. These
mice were randomly assigned to two different groups, receiv-
ing either control or compound ID#704946-supplemented
diet for 9 weeks. Compared with sham mice at 10 weeks,
MI-induced mice developed typical signs of CHF, as evidenced
by pulmonary congestion (i.e. increased lung weight) and
greater cardiac mass (Table 1). In addition, echocardiography
revealed an enlarged left ventricle (signiﬁcant increase LVEDD
and LVESD) and impaired LV function (reduction in LVEF and
LVFS) (Table 1). Mean infarct size was ~30% (Figure 1). No
signiﬁcant differences in lung or cardiac parameters were
detected between compound ID#704946-treated and non-
treated CHF animals, suggesting groups were well matched
in terms of disease severity.
Chronic heart failure-induced diaphragm myopathy
Compared with sham animals, mice with CHF on control chow
developed a diaphragm myopathy at week 10: signiﬁcant
muscle weakness in the diaphragm was demonstrated across
a range of stimulation frequencies (Figure 2A), with maximal
force reduced by 21% (Figure 2B). An impairment between
sham and CHF animals was also apparent from power
Figure 3 Cross-sectional area (A, B) and ﬁbre-type distribution (C, D) was evaluated in diaphragm sections from all three groups. Parafﬁn sections of
the diaphragm were stained with periodic acid–Schiff (A), and the cross-sectional area was determined by ImageJ (B). The distribution of type I and
type II was quantiﬁed in diaphragm samples from all three groups, after staining parafﬁn sections with a myosin heavy chain slow isoform antibody
(dark brown ﬁbres = type I ﬁbres; non-stained ﬁbres = type II ﬁbres) (D). Data are presented as mean ± standard error of the mean. CHF, chronic heart
failure.
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generation measured in ﬁbre bundles (Figure 2C), with peak
power reduced by 28% (Figure 2D). This muscle dysfunction
was accompanied by muscle atrophy, as evidenced by a 21%
reduction in ﬁbre CSA in CHF (Figure 3A and 3B).
Feeding with compound ID#704946 attenuates
diaphragm myopathy in chronic heart failure
Consistent with our previous report,19 feeding of compound
ID#704946 was well tolerated by the mice, and food intake
did not change (data not shown). Compound feeding resulted
in signiﬁcant contractile beneﬁts to the diaphragm: maximal
force (Figure 2A and 2B) and peak power (Figure 2C and
2D) were improved, while ﬁbre atrophy was only slightly
but not signiﬁcantly improved (Figure 3A and 3B). No differ-
ence in skeletal muscle ﬁbre type I proportion was evident
between the three groups (Figure 3C and 3D).
Proteome analyses
To generate hypotheses on the molecular mechanisms un-
derlying the observed physiological changes and beneﬁts,
we next performed comparative quantitative proteomic
analysis of diaphragm tissue from sham, CHF, and CHF + com-
pound-treated mice. Using standard statistical tests, several
proteins were identiﬁed to be statistically different (e.g.
TNNT3, Timm9, Ccdc5, Adi1, Ptges3, and Ndufa3). After ap-
plying multiple hypothesis testing (Benjamini–Hochberg;
corrected P < 0.05) for comparison of CHF mice with and
without compound feeding, only Mrps5 (mitochondrial ribo-
somal protein 5) remained as a signiﬁcantly up-regulated pro-
tein (P = 0.02; Figure 4A). This ﬁnding is reinforced by the fact
that the protein is also found signiﬁcantly enriched in the
CHF + compound vs. sham comparison. Western blotting
was used to conﬁrm this difference in all animals used in the
study (Figure 4B), and as a result, mitochondrial dysfunction
was hypothesized to be involved in CHF-induced myopathy.
Compound ID#704946 treatment normalizes
mitochondrial metabolism and MuRF2 expression
Because proteomic proﬁling data generated the hypothesis of
an impaired mitochondrial homeostasis, we proceeded with
measuring enzymatic activities of key mitochondrial enzymes.
Measuring speciﬁc enzyme activity of mitochondrial enzymes
including CS (Figure 5A), SDH (Figure 5B), and mitochondrial
complex I (Figure 5C) revealed a signiﬁcant reduction by 21,
28, and 27%, respectively, in the diaphragm of CHF animals
when compared with sham. No difference was noted for cre-
atine kinase (Figure 5D). The amount of mitochondria in dia-
phragm tissue, as assessed by the protein expression of the
Figure 4 Diaphragm tissues from mice sacriﬁced after completion of the
myocardial infarction-compound feeding intervention study was charac-
terized by mass spectrometry-based quantitative proteomics analysis.
(A) Mrps5, a mitochondrial-cytosolic shuttle protein in charge of protein
initiation and elongation in the mitochondrial ribosome, is decreased sig-
niﬁcantly in the chronic heart failure (CHF) group in comparison with both
the sham + compound control group and the CHF + compound group, re-
spectively. Each data point represents protein ratio data between two
mice. Relative changes in protein ratio are shown on the y-axis as log2.
By Bayesian moderated t-testing as implemented in the R package limma
and after multiple hypothesis testing correction (Benjamini–Hochberg),
corrected P values are 0.02 for CHF + compound vs. CHF or for
sham + compound vs. CHF. Proteins with P < 0.05 before Benjamini–
Hochberg correction were not included at this stage. (B) Western blot
analysis was performed for Mrps5 in the diaphragm of all animals in-
cluded into the study. A signiﬁcant reduction of Mrps5 expression was
noted in CHF, which was reversed by compound ID#704946 feeding. A
representative western blot is shown, and data are presented as
mean ± standard error of the mean.
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Figure 5 Enzyme activities of citrate synthase (A), succinate dehydrogenase (B), mitochondrial complex I (C), and creatine kinase (D). In addition, pro-
tein expression of mitochondrial porin of the outer mitochondrial membrane (E) and TOM-20 (F) was quantiﬁed in diaphragm samples from all animals
in the three groups [sham, chronic heart failure (CHF), and CHF + 704946]. A representative western blot for the detection of porin, TOM-20, and
GAPDH is shown (G). Our data revealed a signiﬁcant down-regulation of citrate synthase and succinate dehydrogenase activity and porin and TOM-
20 expression in CHF when compared with sham, but this was attenuated in mice fed the compound ID#704946. No difference in creatine kinase ac-
tivity was observed between the three groups. Data are presented as mean ± standard error of the mean.
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mitochondrial porin expression (Figure 5E) and TOM-20 (Fig-
ure 5F), was also signiﬁcantly reduced in CHF mice. Consistent
with effects on mitochrondrial functions, treatment with
compound ID#704946 partially improved CS, SDH, and mito-
chondrial complex I enzyme activity (Figure 5A–C) and re-
sulted in near-normal porin and a modest, but statistically
signiﬁcant, improvement in TOM-20 expression (Figure 5E
and 5F). In contrast, when assessing cytoplasmic enzymes
for glycolysis and fatty acid metabolism (glycolysis: pyruvate
kinase and lactate dehydrogenase; fatty acid metabolism: β-
hydroxyacyl-COA dehydrogenase), no difference was de-
tected between the three groups (Figure 6A–C). We further
evaluated how the expression of MuRF1 and MuRF2, an iso-
form of MuRF1, responded to the development of CHF and
feeding with compound ID#704946. MuRF1 and MuRF2
expression was signiﬁcantly up-regulated in the CHF group
(Figure 7A and 7B), and this was prevented by treatment with
compound ID#704946 (Figure 7A and 7B). Quantifying the ex-
pression of telethonin, a MuRF1 target protein, a trend
(P = 0.08) towards a reduced expression in the CHF group
was observed, which was not evident in the compound
ID#704946-treated group (Figure 7C).
Treatment of myotubes with compound ID#704946
Transcriptome analysis of C2C12 myotubes treated for
20 min with compound ID#704946 was performed by real-
time–reverse transcription PCR and next-generation se-
quencing. Analysing the expression of pre-speciﬁed genes
(MafBx, MuRF1 and MuRF2, Tom20, and porin) detected
only small minor changes (4–10% reduction by compound
ID#704946) (Supporting Information, Figure S2). Running un-
biased next-generation sequencing of the samples revealed
that out of 16 383 genes in the reference, 13% (2165 genes)
did not have enough read counts to be part of the analysis
(mean count of reads across samples was <1). No genes
were identiﬁed as outliers, and 87 genes (0.53%) were found
differentially expressed between control and treatment but
with relative small changes (log2 fold change <±1). Out of
the 87genes, 63 had higher expression in the treated sam-
ples, and 24 had lower expression in the treated samples.
For a detailed view of the altered genes, see Supporting
Information, Table S2.
Differential scanning ﬂuorimetry analysis
In vitro, compound ID#704946 signiﬁcantly lowers the melting
temperature of ‘MuRF1 central’, as indicated by DSF (Figure
8). The ﬁrst derivative of the ﬂuorescence wavelength ratio
of 350/330 nm upon thermal protein unfolding was used to
calculate transition midpoint (Tm) of single and multiple
transition states. Tm of MuRF1 central in PBS was 65.2 °C
and was only negligible changed to 65.8 °C by the addition
of 1% DMSO. In contrast, a strong effect on the thermal
unfolding of MuRF1 was observed by the addition of com-
pound ID#704946. Compound ID#704946 destabilized MuRF1
as indicated by the signiﬁcantly reduced main Tm of 52.5 °C.
Figure 6 Enzyme activities of lactate dehydrogenase (A), pyruvate kinase
(B), and β-hydroxyacyl-COA dehydrogenase (C) were quantiﬁed in dia-
phragm samples from all animals in the three groups [sham, chronic
heart failure (CHF), and CHF + 704946]. No difference for these enzymes
was observed between the three groups. Data are presented as
mean ± standard error of the mean.
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Discussion
It is well established that the development of CHF in
patients is associated with skeletal muscle atrophy and dys-
function, which contributes to exercise intolerance and dys-
pnoea.19,20,22,37–39 A decline in force generation of ~20% in
the diaphragm is apparent as soon as 72 h post-MI,20 ap-
proaching the magnitude observed in end-stage CHF.22 Stud-
ies on patient biopsies and on murine models suggest that
the underlying mechanisms are complex and include an acti-
vation of the UPS, autophagy, inﬂammatory response, and
apoptosis (for review40–42). In this multivariate interplay, in-
duction of MuRF1/MuRF2 has, however, been recognized as
an important step, in particular for ﬁbre atrophy and
dysfunction.43,44 In the present study, we thus tested the po-
tential therapeutic beneﬁt of the recently described MuRF1
inhibitor compound ID#70494619 in a clinically relevant
model of CHF, and the results of the study can be summa-
rized as follows:
i The development of CHF is associated with diaphragm at-
rophy and dysfunction, which is signiﬁcantly reversed by
compound ID#704946.
ii Enzymes involved in mitochondrial energy production and
mitochondrial homeostasis were signiﬁcantly impaired in
diaphragm tissue during CHF, whereas treatment with
compound ID#704946 essentially normalized their
activity/expression.
Figure 7 Protein expression of MuRF1 (A), MuRF2 (B), and telethonin (C) was quantiﬁed by western blot analysis. MuRF1 and MuRF2 were signiﬁcantly
up-regulated in the chronic heart failure (CHF) group (A, B), which was attenuated in the CHF-704946 group. A bigger effect of compound ID#704946
was seen for MuRF2 when compared with MuRF1. For telethonin expression, a trend towards lower expression was evident in the CHF group, which
was attenuated after compound feeding (C) Data are presented as mean ± standard error of the mean.
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iii Feeding with compound ID#704946 had no apparent un-
desired side effects such as on the reduced cardiac con-
tractility and myocardial hypertrophy response in this
murine heart failure model.
Treatment of diaphragm dysfunction and atrophy
by compound ID#704946
Diaphragmatic weakness of 15–20% as reported for heart fail-
ure in the present study is comparable with other diseases
like mechanical ventilation and sepsis,45,46 critically ill pa-
tients,47 or pulmonary hypertension48 and is reported to be
of clinical relevance with respect to mortality.49 In the pres-
ent study, we tested the effects of compound ID#704946
when fed to animals 7 days after the MI for 9 weeks as a sec-
ondary prevention. Earlier observations from our group doc-
umented that 3 days post-MI diaphragmatic function is
signiﬁcantly impaired.20 Intriguingly, in the present secondary
prevention setting, compound ID#704946 reversed dia-
phragm function to nearly normal values without big effects
on muscle mass. This is in contrast to observations made ear-
lier in a cardiac cachexia model where an effect of compound
ID#704946 was seen on function and muscle mass.19 This
possibly relates to a diversity of underlying mechanisms,
length of intervention, or pharmacokinetics, but further stud-
ies are necessary to address this in more detail. Other ap-
proaches to counteract muscle atrophy in different models
of wasting conditions have been recently described and in-
clude administration of β-hydroxy β-methylbutyrate
(HMB),50 1,25-dihydroxyvitamin D,51 anti-interleukin-6 anti-
body treatment,51 IκB kinase-β inhibition by IMD-0354,52 or
direct inhibition of the UPS by MG132.53–55 In the majority
of these studies, however, the pharmacological agent was ad-
ministered prior to initiating muscle atrophy by hindlimb sus-
pension51 or did not prevent muscle atrophy.52 The use of
MG132 is discussed controversially with a subset of studies
reporting positive effects on muscle atrophy induced by
hindlimb unloading,53,55 or tumour,54 whereas others saw
no effects.56,57 Importantly, when assessing the impact of
MG132 on muscle force, no positive effect was obvious.56
This is in clear contrast to compound ID#704946 treatment,
where improved ﬁbre contractility was evident. Taken to-
gether, the chemical knock-down of MuRF1 and MuRF2 by
compound ID#704946 appears a viable treatment strategy
to follow up on the amelioration of diaphragm dysfunction
in cardiac failure. Previous studies on MuRF1 knockout mice
suggested an increased vulnerability for cardiac hypertrophy
during pressure overload.58 It is of note that in the present
study, no exaggerated cardiac hypertrophic response was ev-
ident when feeding compound ID#704946 during the devel-
opment of CHF, an observation that nevertheless requires
validation in additional studies on non-stressed animals.
Potential underlying mechanisms
The molecular analyses performed in the present study
suggest that a decay of mitochondrial function is involved in
CHF-induced muscle dysfunction and that compound
ID#704946 is able to rescue mitochondrial impairment.
Comparing protein expression by quantitative proteomic
analysis and follow-up for speciﬁc mitochondrial enzyme
activities conﬁrmed diminished mitochondrial energy produc-
tion and homeostasis in CHF as reversed by treatment with
compound ID#704946. In particular, Mrps5 was the protein
with the highest signiﬁcant induction by compound
ID#704946, which was conﬁrmed by conventional western
blot analysis. Mrps5, a member of the family of mitochondrial
ribosomal proteins, was ﬁrst described in Caenorhabditis
elegans, where it was causally involved in regulating
lifespan.59 Knock-down of Mrps5 resulted in reduced mito-
chondrial respiration, and the worms displayed reduced ATP
levels and CS activity.59 Consistent with this, we detected a
clear reduction of mitochondrial complex I activity, which
was reversed by compound ID#704946 treatment. The essen-
tial role of mitochondrial dysfunction in the pathology of
Figure 8 The effect of compound ID#704946 on MuRF1 protein stability
was determined in vitro by differential scanning ﬂuorimetry. Changes in
the intrinsic protein ﬂuorescence in a thermal gradient were monitored
at 350 and 330 nm, respectively. The ﬁrst derivative of the ﬂuorescence
wavelength ratio of 350/330 nm upon thermal protein unfolding was
used to calculate transition midpoint (Tm) of single and multiple transi-
tion states. Tm of MuRF1 central in phosphate-buffered saline (solid line)
was 65.2 °C and was only negligible changed to 65.8 °C by the addition of
1% DMSO (dashed line). In contrast, a strong effect on the thermal
unfolding of MuRF1 was observed by the addition of compound
ID#704946 (dotted line). Compound ID#704946 destabilized MuRF1 as in-
dicated by the signiﬁcantly reduced main Tm of 52.5 °C.
MuRF inhibition in chronic heart failure 11
Journal of Cachexia, Sarcopenia and Muscle 2019
DOI: 10.1002/jcsm.12448
muscle atrophy is described in many muscle atrophy models
including disuse, diabetes, ageing, and CHF.39,60–62 In the
context of CHF-induced diaphragm weakness, a pivotal
involvement is further supported by the observation that
reduction of mitochondrial reactive oxygen species by
MitoTEMPO counteracted the dysfunction.63
The exact molecular mechanism by which compound
ID#704946 exerts these beneﬁcial effects on the mitochon-
dria remains to be determined, as this compound was origi-
nally identiﬁed as an inhibitor of the interaction between
the MuRF1 and the giant myoﬁbrillar protein titin. Our DSF
results suggest a destabilization of MuRF1’s coiled-coil region
caused by compound ID#704946 in vitro. With regard to sig-
nalling effects caused by compound ID#704946 during feed-
ing in vivo, future studies are required to determine if
MuRF1 destabilization occurs also in vivo (possibly accounting
for the modest reduction of MuRF1 steady-state expression
levels) or if binding of compound ID#704946 to MuRF1’s
central region attenuates target recognition (possibly
inhibiting binding to titin and/or increasing myocellular
telethonin levels, see the succeeding texts). Previous studies
on the cellular interacting partners of MuRF1 identiﬁed
numerous myoﬁbrillar proteins and also many genes involved
in mitochondrial biology and energy metabolism.64 Consis-
tent with this, transgenic overexpression of MuRF1 in skeletal
muscle shows perturbed carbohydrate metabolism and
glucose tolerance in mice.26 Therefore, we previously specu-
lated that an induction of MuRF1 in the skeletal muscles dur-
ing chronic stress (e.g. CHF65,66) may trigger MuRF1 to
ubiquitinate nuclear-encoded proteins of the mitochondrial
respiratory chain during their cytoplasmic transport to the
mitochondria in an effort to conserve energy metabolites.
Accordingly, treatment by compound ID#704946 could re-
verse this detrimental effect in chronic stress states where
MuRF1 acts as a negative regulator of mitochondrial energy
production. In accordance with this hypothesis and our previ-
ous report,19 a signiﬁcant up-regulated MuRF1 expression
was evident in CHF, which was blunted by compound
ID#704946. In line with the effect of compound ID#704946
on MuRF1 expression, also a trend towards a reduced expres-
sion of telethonin, a known substrate for MuRF1,67,68 was
seen in CHF, which was also blunted in the compound-
treated group. To our surprise, we also detected a signiﬁcant
modulation of MuRF2 by compound ID#704946. A possible
explanation why compound ID#704946 also attenuates
MuRF2 induction is that the recombinant MuRF1 fragment,
which was used to ﬁsh compound ID#704946 from the in-
house EMBL compound collection, corresponds to its central
coiled-coil domain (MuRF1cc) that is highly conserved be-
tween MuRF1 and MuRF2.67 Therefore, compound
ID#704946 may act on both MuRF1 and MuRF2, and studies
are ongoing to determine this. Future studies are also
required to determine if the modest reduction of MuRF1 ex-
pression in the compound ID#704946-treated group, or
rather an attenuated interaction of MuRF1 with its target
proteins, or mechanisms unrelated to both underlie its pro-
tective effects. Furthermore, preliminary high-performance
liquid chromatography–mass spectrometry studies indicated
after intraperitoneal or oral delivery a rapid appearance
in serum, followed by a fast metabolization. Therefore,
additional studies are mandatory to determine the metabo-
lism and bioavailability of compound ID#704946.
Study limitations
An important principal limitation of our study is the rele-
vance of the used murine model for human heart failure:
the underlying mechanisms may principally differ between
human and mice, but in this study, we tried to control for
this by following CHF closely by echocardiography and
selecting mice as appropriate to mimic the human condition.
Another limitation is that the used compound is unrelated to
other known drugs. Presently, no pharmacological data or
data on toxicity, pharmacokinetics, and bioavailability are
available. As such, follow-up studies are needed to deter-
mine if compound ID#704946 indeed can be a future drug
candidate.
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#704946 for 20 min by qRT-PCR. Values are expressed as
fold changes vs. control.
Table S1: Primer Sequences
Table S2: List of genes signiﬁcantly altered by ID#704946
References
1. Wannamethee GS, Shaper AG, Lennon L,
Whincup PH. Decreased muscle mass and
increased central adiposity are indepen-
dently related to mortality in older men.
Am J Clin Nutr 2007;86:1339–1346.
2. Rantanen T, Harris T, Leveille SG, Visser M,
Foley D, Masaki K, et al. Muscle strength
and body mass index as long-term predic-
tors of mortality in initially healthy men.
J Gerontol A Biol Sci Med Sci 2018;55:
M168–M173.
3. Martin L, Birdsell L, MacDonald N, Reiman
T, Clandinin MT, McCargar LJ, et al. Cancer
cachexia in the age of obesity: skeletal
muscle depletion is a powerful prognostic
factor, independent of body mass index.
J Clin Oncol 2013;31:1539–1547.
4. Fülster S, Tacke M, Sandek A, Ebner N,
Tschöpe C, Doehner W, et al. Muscle
wasting in patients with chronic heart fail-
ure: results from the studies investigating
co-morbidities aggravating heart failure
(SICA-HF). Eur Heart J 2013;34:512–519.
5. Lecker SH, Solomon V, Mitch WE, Goldberg
AL. Muscle protein breakdown and the crit-
ical role of the ubiquitin–proteasome path-
way in normal and disease states. J Nutr
1999;129:227S.
6. Lecker SH, Jagoe RT, Gilbert A, Gomes M,
Baracos VE, Bailey J, et al. Multiple types
of skeletal muscle atrophy involve a com-
mon program of changes in gene expres-
sion. FASEB J 2004;18:39–51.
7. Sandri M. Protein breakdown in muscle
wasting: role of autophagy–lysosome and
ubiquitin–proteasome. Int J Biochem Cell
Biol 2013;45:2121–2129.
8. Cohen S, Brault JJ, Gygi SP, Glass DJ,
Valenzuela DM, Gartner C, et al. During
muscle atrophy, thick, but not thin,
ﬁlament components are degraded by
MuRF1-dependent ubiquitylation. J Cell
Biol 2009;185.
9. Cohen S, Nathan JA, Goldberg AL. Muscle
wasting in disease: molecular mechanisms
and promising therapies. Nat Rev Drug
Discov 2014;14:58–74.
10. Attaix D, Ventadour S, Codran A, Bechet D,
Taillandier D, Combaret L. The ubiquitin–
proteasome system and skeletal muscle
wasting. Essays Biochem 2005;41:173–186.
11. Adams V, Mangner N, Gasch A, Krohne C,
Gielen S, Hirner S, et al. Induction of
MuRF1 is essential for TNF-α-induced loss
of muscle function in mice. J Mol Biol
2008;384:48–59.
12. Bodine SC, Latres E, Baumhueter S, Lai VKM,
Nunez L, Clarke BA, et al. Identiﬁcation of
ubiquitin ligases required for skeletal
muscle atrophy. Science 2001;294:
1704–1708.
13. Li YP, Chen Y, Li AS, Reid MB. Hydrogen
peroxide stimulates ubiquitin-conjugating
activity and expression of genes for speciﬁc
E2 and E3 proteins in skeletal muscle
myotubes. Am J Physiol Cell Physiol
2003;285:C806–C812.
14. Baehr LM, Furlow JD, Bodine SC. Muscle
sparing in muscle RING ﬁnger 1 null mice:
response to synthetic glucocorticoids.
J Physiol 2011;589:4759–4776.
15. Eddins MJ, Marblestone JG, Suresh Kumar
KG, Leach CA, Sterner DE, Mattern MR,
et al. Targeting the ubiquitin E3 ligase
MuRF1 to inhibit muscle atrophy. Cell
Biochem Biophys 2011;60:113–118.
16. Castillero E, Alamdari N, Lecker SH,
Hasselgren PO. Suppression of atrogin-1
and MuRF1 prevents dexamethasone-
induced atrophy of cultured myotubes.
Metabolism 2013;62:1495–1502.
17. Clarke BA, Drujan D, Willis MS, Murphy LO,
Corpina RA, Burova E, et al. The E3 ligase
MuRF1 degrades myosin heavy chain pro-
tein in dexamethasone-treated skeletal
muscle. Cell Metab 2007;6:376–385.
18. Gielen S, Sandri M, Kozarez I, Kratsch J,
Teupser D, Thiery J, et al. Exercise training
attenuates MuRF-1 expression in the skele-
tal muscle of patients with chronic heart
failure independent of age: the randomized
Leipzig Exercise Intervention in Chronic
Heart Failure and Aging (LEICA) catabolism
study. Circulation 2012;125:2716–2727.
19. Bowen TS, Adams V, Werner S, Fischer T,
Vinke P, Brogger MN, et al. Small-molecule
inhibition of MuRF1 attenuates skeletal
muscle atrophy and dysfunction in cardiac
cachexia. J Cachexia Sarcopenia Muscle
2017;8:939–953.
20. Bowen TS, Mangner N, Werner S, Glaser S,
Kullnick Y, Schrepper A, et al. Diaphragm
muscle weakness in mice is early-onset
post-myocardial infarction and associated
with elevated protein oxidation. J Appl
Physiol 2015;118:11–19.
21. Mangner N, Weikert B, Bowen TS, Sandri
M, Höllriegel R, Erbs S, et al. Skeletal mus-
cle alterations in chronic heart failure: dif-
ferential effects on quadriceps and
diaphragm. J Cachexia Sarcopenia Muscle
2015;6:381–390.
22. Mangner N, Bowen TS, Werner S, Fischer T,
Kullnick Y, Oberbach A, et al. Exercise
training prevents diaphragm contractile
dysfunction in heart failure. Med Sci Sports
Exerc 2016;48:2118–2124.
23. Cox J, Mann M. MaxQuant enables high
peptide identiﬁcation rates, individualized
p.p.b.-range mass accuracies and
proteome-wide protein quantiﬁcation. Nat
Biotechnol 2008;26:1367–1372.
24. Elias JE, Gygi SP. Target-decoy search strat-
egy for increased conﬁdence in large-scale
protein identiﬁcations by mass spectrome-
try. Nat Methods 2007;4:207–214.
25. Boersema PJ, Raijmakers R, Lemeer S, Mo-
hammed S, Heck AJR. Multiplex peptide
stable isotope dimethyl labeling for quanti-
tative proteomics. Nat Protoc 2009;4:
484–494.
26. Hirner S, Krohne C, Schuster A, Hoffmann
S, Witt S, Erber R, et al. MuRF1-dependent
regulation of systemic carbohydrate me-
tabolism as revealed from transgenic
mouse studies. J Mol Biol 2008;379:
666–677.
27. Mukherjee A, Srere PA, Frenkel EP. Studies
of the mechanism by which hepatic citrate
synthase activity increases in vitamin
B12 deprivation. J Biol Chem 1976;251:
2155–2160.
28. Vanderlinde RE. Measurement of total lac-
tate dehydrogenase activity. Ann Clin Lab
Sci 1985;15:13–31.
29. Dzeja PP, Pucar D, Redﬁeld MM,
Burnett JC, Terzic A. Reduced activity of
enzymes coupling ATP-generating with
ATP-consuming processes in the failing
myocardium. Mol Cell Biochem 1999;201:
33–40.
30. Takashi O, Takashi H. Occurrence of two 3-
hydroxyacyl-CoA dehydrogenases in rat
liver. Biochim Biohphys Acta 1979;574:
258–267.
31. Schwarzer M, Osterholt M, Lunkenbein A,
Schrepper A, Amorim P, Doenst T. Mito-
chondrial reactive oxygen species produc-
tion and respiratory complex activity in
MuRF inhibition in chronic heart failure 13
Journal of Cachexia, Sarcopenia and Muscle 2019
DOI: 10.1002/jcsm.12448
rats with pressure overload-induced heart
failure. J Physiol 2014;592:3767–3782.
32. Mrosek M, Labeit D, Witt S, Heerklotz H,
von Castelmur E, Labeit S, et al. Molecular
determinants for the recruitment of the
ubiquitin-ligase MuRF-1 onto M-line titin.
FASEB J 2007;21:1383–1392.
33. Schauer A, Adams V, Poitz DM, Barthel P,
Joachim D, Friedrich J, et al. Loss of Sox9
in cardiomyocytes delays the onset of
cardiac hypertrophy and ﬁbrosis. Int J
Cardiol 2019;282:68–75.
34. Dobin A, Davis CA, Schlesinger F, Drenkow
J, Zaleski C, Jha S, et al. STAR: ultrafast uni-
versal RNA-seq aligner. Bioinformatics
2013;29:15–21.
35. Anders S, Pyl PT, Huber W. HTSeq—a Py-
thon framework to work with high-
throughput sequencing data. Bioinformat-
ics 2015;31:166–169.
36. Love MI, Huber W, Anders S. Moderated
estimation of fold change and dispersion
for RNA-seq data with DESeq2. Genome
Biol 2014;15:550–571.
37. Ribeiro JP, Chiappa GR, Neder JA, Franken-
stein L. Respiratory muscle function and
exercise intolerance in heart failure. Curr
Heart Fail Rep 2009;6:95–101.
38. Hughes PD, Polkey MI, Lou Harries M,
Coats AJS, Moxham J, Green M. Dia-
phragm strength in chronic heart failure.
Am J Respir Crit Care Med 1999;160:
529–534.
39. Bowen TS, Rolim NPL, Fischer T, Baekkerud
FH, Medeiros A, Werner S, et al. Heart
failure with preserved ejection fraction in-
duces molecular, mitochondrial, histologi-
cal, and functional alterations in rat
respiratory and limb skeletal muscle. Eur J
Heart Fail 2015;17:263–272.
40. Lecker SH. Ubiquitin–protein ligases in
muscle wasting: multiple parallel path-
ways? Curr Opin Clin Nutr Metab Care
2004;6:271–275.
41. Bowen TS, Schuler G, Adams V. Skeletal
muscle wasting in cachexia and sarcopenia:
molecular pathophysiology and impact of
exercise training. J Cachexia Sarcopenia
Muscle 2015;6:197–207.
42. Bonaldo P, Sandri M. Cellular and molecu-
lar mechanisms of muscle atrophy. Dis
Model Mech 2013;6:25–39.
43. Levine S, Biswas C, Dierov J, Barsotti R,
Shrager JB, Nguyen T, et al. Increased pro-
teolysis, myosin depletion, and atrophic
AKT–FOXO signaling in human diaphragm
disuse. Am J Respir Crit Care Med 2011;
183:483–490.
44. Hooijman PE, Beishuizen A, Witt CC, de
Waard MC, Girbes ARJ, Spoelstra-de Man
AME, et al. Diaphragm muscle ﬁber weak-
ness and ubiquitin–proteasome activation
in critically ill patients. Am J Respir Crit Care
Med 2015;191:1126–1138.
45. Le Dinh M, Carreira S, Obert J, Gayan-
Ramirez G, Riou B, Beuvin M, et al.
Prolonged mechanical ventilation worsens
sepsis-induced diaphragmatic dysfunction
in the rat. PLoS ONE 2018;13:e0200429.
46. van Hees HWH, Schellekens WJ, Andrade
Acuna GL, Linkels M, Hafmans T,
Ottenheijm CAC, et al. Titin and diaphragm
dysfunction in mechanically ventilated rats.
Intensive Care Med 2012;38:702–709.
47. van den Berg M, Hooijman PE, Beishuizen
A, de Waard MC, Paul MA, Hartemink KJ,
et al. Diaphragm atrophy and weakness in
the absence of mitochondrial dysfunction
in the critically ill. Am J Respir CritCare
Med 2017;196:1544–1558.
48. Ahn B, Empinado HM, Al-Rajhi M, Judge
AR, Ferreira LF. Diaphragm atrophy and
contractile dysfunction in a murine model
of pulmonary hypertension. PLoS ONE
2013;8:e62702.
49. Demoule A, Jung B, Prodanovic H, Molinari
N, Chanques G, Coirault C, et al. Diaphragm
dysfunction on admission to the intensive
care unit. Prevalence, risk factors, and
prognostic impact—a prospective study.
Am J Respir CritCare Med 2013;188:
213–219.
50. Noh KK, Chung KW, Choi YJ, Park MH, Jang
EJ, Park CH, et al. β-Hydroxy β-
methylbutyrate improves dexamethasone-
induced muscle atrophy by modulating
the muscle degradation pathway in SD
rat. PLoS ONE 2014;9:e102947.
51. Yakabe M, Ogawa S, Ota H, Iijima K, Eto M,
Ouchi Y, et al. Inhibition of interleukin-6
decreases atrogene expression and amelio-
rates tail suspension-induced skeletal mus-
cle atrophy. PLoS ONE 2018;13:e0191318.
52. Belova SP, Shenkman BS, Kostrominova TY,
Nemirovskaya TL. Paradoxical effect of
IKKβ inhibition on the expression of E3
ubiquitin ligases and unloading-induced
skeletal muscle atrophy. Physiol Rep
2017;5:e13291.
53. Caron AZ, Haroun S, Leblanc E, Trensz F,
Guindi C, Amrani A, et al. The proteasome
inhibitor MG132 reduces immobilization-
induced skeletal muscle atrophy in mice.
BMC Musculoskelet Disord 2011;12:185.
54. Zhang L, Tang H, Kou Y, Li R, Zheng Y, Wang
Q, et al. MG132-mediated inhibition of the
ubiquitin–proteasome pathway amelio-
rates cancer cachexia. J Cancer Res Clin
Oncol 2013;139:1105–1115.
55. Jamart C, Raymackers JM, Li An G,
Deldicque L, Francaux M. Prevention of
muscle disuse atrophy by MG132 protea-
some inhibitor. Muscle Nerve
2011;43:708–716.
56. Supinski GS, Vanags J, Callahan LA. Effect
of proteasome inhibitors on endotoxin-
induced diaphragm dysfunction. Am J
Physiol Lung Cell Mol Physiol 2009;
L994–L1001.
57. Smuder AJ, Nelson WB, Hudson MB,
Kavazis AN, Powers SK. Inhibition of the
ubiquitin–proteasome pathway does not
protect against ventilatory-induced
accelerated proteolysis or atrophy in the
diaphragm. Anesthesiology 2014;121:
115–126.
58. Willis MS, Ike C, Li L, Wang DZ, Glass DJ,
Patterson C. Muscle ring ﬁnger 1, but not
muscle ring ﬁnger 2, regulates cardiac hy-
pertrophy in vivo. Circ Res 2007;
100:456–459.
59. Houtkooper RH, Mouchiroud L, Ryu D,
Moullan N, Katsyuba E, Knott G, et al.
Mitonuclear protein imbalance as a con-
served longevity mechanism. Nature
2013;497:451–457.
60. Romanello V, Sandri M. Mitochondrial bio-
genesis and fragmentation as regulators of
protein degradation in striated muscles.
J Mol Cell Cardiol 2013;55:64–72.
61. Liu J, Peng Y, Cui Z, Wu Z, Qian A, Shang P,
et al. Depressed mitochondrial biogenesis
and dynamic remodelingin mouse tibialis
anterior and gastrocnemius induced by 4-
week hindlimb unloading. IUBMB Life
2012;64:901–910.
62. Bowen TS, Eisenkolb S, Drobner J, Fischer
T, Werner S, Linke A, et al. High-intensity
interval training prevents oxidant-
mediated diaphragm muscle weakness in
hypertensive mice. FASEB J 2016;31:60–71.
63. Laitano O, Ahn B, Patel N, Coblentz PD,
Smuder AJ, Yoo JK, et al. Pharmacological
targeting of mitochondrial reactive oxygen
species counteracts diaphragm weakness
in chronic heart failure. J Appl Physiol
2016;120:733–742.
64. Mcparland C, Krishnan B, Wang Y,
Gallagher CG. Inspiratory muscle weakness
and dyspnea in chronic heart failure. Am
Rev Respir Dis 1992;146:467–472.
65. Seiler M, Bowen TS, Rolim N, Dieterlen MT,
Werner S, Hoshi T, et al. Skeletal muscle al-
terations are exacerbated in heart failure
with reduced compared with preserved
ejection fraction: mediated by circulating
cytokines? Circ Heart Fail 2016;e003027.
66. Carvalho RF, Castan EP, Coelho CA, Lopes
FS, Almeida FLA, Michelin A, et al. Heart
failure increases atrogin-1 and MuRF1 gene
expression in skeletal muscle with ﬁber
type-speciﬁc atrophy. J Mol Histol 2010;
41:81–87.
67. Witt SH, Granzier H, Witt CC, Labeit S.
Murf-1 and Murf-2 target a speciﬁc subset
of myoﬁbrillar proteins redundantly: to-
wards understanding Murf-dependent
ubiquitination. J Mol Biol 2005;350:
713–722.
68. Polge C, Cabantous S, Deval C, Claustre A,
Hauvette A, Bouchenot C, et al. A muscle-
speciﬁc MuRF1–E2 network requires stabi-
lization of MuRF1–E2 complexes by
telethonin, a newly identiﬁed substrate. J
Cachexia Sarcopenia Muscle 2018;9:
129–145.
69. von Haehling S, Morley JE, Coats Andrew
JS, Anker SD. Ethical guidelines for publish-
ing in the Journal of Cachexia, Sarcopenia
and Muscle: update 2017. J Cachexia
Sarcopenia Muscle 2017;8:1081–1083.
14 V. Adams et al.
Journal of Cachexia, Sarcopenia and Muscle 2019
DOI: 10.1002/jcsm.12448
